News & Events about Evelo Biosciences Inc.
Ticker Report
2 months ago
Evelo Biosciences (NASDAQ:EVLO Get Rating) had its target price lowered by BMO Capital Markets from $10.00 to $5.00 in a research note released on Friday morning, The Fly reports. Several other research firms have also issued reports on EVLO. Jefferies Financial Group lowered shares of Evelo...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (Evelo or the Company) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported ...
Evelo Biosciences, Inc. (NASDAQ:EVLO Get Rating) was the target of unusually large options trading activity on Wednesday. Investors bought 1,885 put options on the company. This is an increase of approximately 1,101% compared to the typical daily volume of 157 put options. Wall Street Analyst Weigh ...
Ticker Report
5 months ago
Evelo Biosciences, Inc. (NASDAQ:EVLO Get Rating) was the target of unusually large options trading activity on Wednesday. Investors bought 1,885 put options on the company. This is an increase of approximately 1,101% compared to the typical daily volume of 157 put options. Wall Street ...
Globe Newswire
5 months ago
CAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced it has entered into a senior secured loan agreement...